SCIENCE@home

Prospective, Pilot, Open‐Label, Short‐Term Study of Conversion to Leflunomide Reverses Chronic Renal Allograft Dysfunction

K. Hardinger,Candace Wang,M. Schnitzler,B. Miller,M. Jendrisak,S. Shenoy,J. A. Lowell,D. Brennan

Published 2002 in American Journal of Transplantation

ABSTRACT

Leflunomide (LEF) is a synthetic isoxazole derivative with anti‐inflammatory and antiviral properties, which has been reported to prevent acute rejection and delay progression of chronic allograft nephropathy (CAN) in animal models. We performed a pilot, crossover trial in 22 renal transplant recipients who were converted from azathioprine (AZA) or mycophenolate mofetil (MMF) to LEF in an effort to slow progression of renal dysfunction [deteriorating renal function (n = 5), cyclosporine (CyA) nephrotoxicity (n = 4) or biopsy‐proven CAN (n = 13)]. Baseline maintenance immunosuppression consisted of CyA, AZA or MMF and prednisone. Six‐month postconversion patient and graft survival was 100% and 91%, respectively. Mean serum creatinine 6 months preconversion was 2.2 ± 0.6 mg/dL, at initiation was 3.0 ± 1.1 mg/dL, and 6 months postconversion was 2.8 ± 1.3 mg/dL. The rate of change in serum creatinine was 35 ± 39%/6 months preconversion and − 5 ± 21%/6 months postconversion to LEF (p = 0.003). Two patients discontinued LEF for diarrhea and myalgia. No readmissions, increase in liver function tests, infections or acute rejection episodes occurred. Mean CyA levels did not change, 146 ± 72 ng/mL pre‐LEF vs. 132 ± 51 ng/mL post‐LEF, p = NS. Conversion to LEF reversed progression of chronic renal allograft dysfunction with minimal toxicity.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-36 of 36 references · Page 1 of 1

CITED BY

Showing 1-59 of 59 citing papers · Page 1 of 1